Evidence map›Paper›PMID 28229377›Full record

ArticleThe patient2017

Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study.

Emma Dures, Sarah Hewlett, Jane Lord, Clive Bowen, Neil McHugh, PROMPT Study Group, William Tillett

Erratum issuedOpen access · hybridAbstract readMulticenter Study
In one paragraph

Article in The patient, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Emma DuresUniversity of the West of England, Bristol, UK. emma2.dures@uwe.ac.uk.
Sarah HewlettUniversity of the West of England, Bristol, UK.
Jane LordUniversity Hospitals Bristol, Bristol, UK.
Clive BowenThe Psoriatic Arthritis Support Group (PsAZZ), Bath, UK.
Neil McHughUniversity of Bath, Bath, UK.
PROMPT Study Group
William TillettRoyal National Hospital for Rheumatic Diseases, Bath, UK.
University of the West of England · GBRoyal National Hospital for Rheumatic Diseases · GBPsoriasis and Psoriatic Arthritis Alliance · GBUniversity Hospitals Bristol NHS Foundation Trust · GB

Funding

Department of Health RP-PG-1212-20007
6 · The paper itself

Abstract

backgroundPsoriatic arthritis (PsA) is a variable and complex inflammatory condition. Symptoms can compromise physical function, reduce quality of life, and accrue significant health costs. Commonly used patient-reported outcomes largely reflect the professionals' perspective, however it is not known whether they capture what is important to patients.

objectiveThe aim of our study was to identify treatment outcomes important to patients with PsA.

methodsEight focus groups that were audio recorded, transcribed, anonymised and analysed using inductive thematic analysis were conducted at five hospital sites. The full data set was analysed by the lead researcher, and subsets analysed by three team members (including patient partners).

resultsOverall, 41 patients sampled for a range of phenotypes and domains of disease activity participated in the study: 20 males; mean age 58 years (range 28-75, standard deviation [SD] 11.4); mean disease duration 9 years (range 0.5-39, SD 8.3); and mean Health Assessment Questionnaire score of 1 (range 0.0-2.5, SD 0.7). Over 60 outcomes were identified and grouped into four themes: (i) symptom alleviation (e.g. pain, fatigue, itchy skin, swelling, and reducing variability); (ii) reduction of disease impact (e.g. tiredness and pain, mobility and dexterity, deteriorating physical fitness, negative emotional responses, and strained relationships and social interactions); (iii) improved prognosis (e.g. slowing down disease progression, maintaining independence, and enhancing quality of life); and (iv) minimisation of treatment harm and burden (e.g. nausea, long-term effects, and administration and monitoring of treatments).

conclusionsOutcomes from treatments that are important to patients, which relate to impacts from PsA and its treatment that range beyond those outcomes commonly measured, were identified. These patient perspectives need to be considered when evaluating treatments.

Indexed as

Quality of LifeAdultAgedArthritis, PsoriaticDisease ProgressionEmotionsFatigueFemaleFocus GroupsHumansInterpersonal RelationsMaleMiddle AgedPatient PreferencePhysical Fitness

Identifiers

PMID28229377
PMCPMC5534194
OpenAlexW2590526904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.